source
- FDA grants accelerated approval to AstraZeneca's oral SERD for breast cancer despite advisory panel oppositionFDA granted accelerated approval to AstraZeneca's oral selective estrogen receptor degrader, Camizestrant, for a specific group of breast cancer patients. The approval was issued on Friday even th…
- Bristol Myers Squibb pauses autoimmune CAR‑T trials after life‑threatening side effectsBristol Myers Squibb announced in early June that it is pausing its CAR‑T therapy trials targeting autoimmune diseases after the trials reported life‑threatening side effects. The company informed…